Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,300 | 1 | 45.6% |
| Food and Beverage | $1,566 | 46 | 21.7% |
| Travel and Lodging | $1,366 | 4 | 18.9% |
| Honoraria | $1,000 | 1 | 13.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $4,928 | 6 | $0 (2019) |
| Horizon Therapeutics plc | $1,020 | 2 | $0 (2020) |
| Amgen Inc. | $346.38 | 10 | $0 (2020) |
| AbbVie Inc. | $277.40 | 18 | $0 (2020) |
| Hikma Pharmaceuticals USA | $185.67 | 10 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $137.64 | 2 | $0 (2023) |
| Radius Health, Inc. | $124.96 | 1 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $109.46 | 1 | $0 (2018) |
| Lilly USA, LLC | $91.15 | 1 | $0 (2018) |
| Celgene Corporation | $11.63 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $125.00 | 1 | AstraZeneca Pharmaceuticals LP ($125.00) |
| 2022 | $12.64 | 1 | AstraZeneca Pharmaceuticals LP ($12.64) |
| 2020 | $1,206 | 6 | Horizon Therapeutics plc ($1,020) |
| 2019 | $5,303 | 22 | PFIZER INC. ($4,928) |
| 2018 | $516.50 | 16 | AbbVie, Inc. ($130.87) |
| 2017 | $69.15 | 6 | Amgen Inc. ($33.75) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/20/2023 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 04/13/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/26/2020 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| Category: KRYSTEXXA | ||||||
| 02/26/2020 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Bone Health | ||||||
| 02/19/2020 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/29/2020 | AbbVie Inc. | RINVOQ (Drug) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: IMMUNOLOGY | ||||||
| 01/22/2020 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/09/2020 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: KRYSTEXXA | ||||||
| 12/05/2019 | AbbVie, Inc. | Rinvoq (Biological) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Immunology | ||||||
| 10/23/2019 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/17/2019 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $124.68 | General |
| Category: Bone Health | ||||||
| 09/26/2019 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: Immunology | ||||||
| 08/15/2019 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/11/2019 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/11/2019 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $133.44 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/03/2019 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/22/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: Immunology | ||||||
| 05/10/2019 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $609.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/10/2019 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $371.20 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/10/2019 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $261.61 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/10/2019 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $252.42 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/09/2019 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/25/2019 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $5.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/24/2019 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $2.89 | General |
| Category: Bone Health | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 780 | 99,718 | $4.2M | $1.1M |
| 2022 | 14 | 538 | 41,605 | $1.5M | $442,149 |
| 2021 | 13 | 412 | 30,914 | $1.1M | $331,751 |
| 2020 | 12 | 342 | 5,793 | $704,568 | $222,341 |
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 17 | 10,450 | $940,500 | $352,223 | 37.5% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 15 | 63,576 | $762,912 | $298,214 | 39.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 19 | 15,350 | $1.1M | $161,379 | 14.6% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2023 | 17 | 3,760 | $853,520 | $111,213 | 13.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 54 | 4,980 | $169,320 | $91,207 | 53.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 60 | 341 | $109,120 | $34,515 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 254 | 467 | $91,532 | $31,525 | 34.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 181 | 285 | $64,980 | $26,703 | 41.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 39 | 146 | $32,850 | $7,275 | 22.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 25 | 120 | $15,000 | $2,567 | 17.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $4,500 | $2,291 | 50.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 57 | 105 | $9,534 | $1,174 | 12.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 24 | 120 | $24,960 | $738.95 | 3.0% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 16 | 30,086 | $361,032 | $140,997 | 39.1% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 12 | 3,375 | $303,750 | $115,517 | 38.0% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2022 | 18 | 1,363 | $309,401 | $52,935 | 17.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 11 | 3,684 | $265,248 | $42,079 | 15.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 23 | 2,220 | $75,480 | $37,499 | 49.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 174 | 315 | $61,740 | $22,075 | 35.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 43 | 85 | $27,200 | $9,578 | 35.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 86 | 94 | $21,432 | $9,343 | 43.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 50 | 122 | $27,450 | $6,591 | 24.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $4,725 | $1,509 | 31.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 22 | 58 | $7,250 | $1,389 | 19.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 17 | 19 | $3,724 | $1,224 | 32.9% |
About Dr. Kiley Toder, M.D
Dr. Kiley Toder, M.D is a Internal Medicine healthcare provider based in Johnston, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/26/2009. The National Provider Identifier (NPI) number assigned to this provider is 1063640225.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kiley Toder, M.D has received a total of $7,232 in payments from pharmaceutical and medical device companies, with $125.00 received in 2023. These payments were reported across 52 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($3,300).
As a Medicare-enrolled provider, Toder has provided services to 2,072 Medicare beneficiaries, totaling 178,030 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Johnston, RI
- Active Since 06/26/2009
- Last Updated 12/22/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1063640225
Products in Payments
- XELJANZ (Drug) $4,928
- KRYSTEXXA (Biological) $1,020
- EVENITY (Biological) $252.57
- Humira (Biological) $241.53
- Mitigare (Drug) $185.67
- SAPHNELO (Biological) $137.64
- Tymlos (Biological) $124.96
- STELARA (Biological) $109.46
- TALTZ (Drug) $91.15
- Enbrel (Biological) $80.92
- RINVOQ (Drug) $17.94
- Rinvoq (Biological) $17.93
- Prolia (Biological) $12.89
- Otezla (Drug) $11.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Johnston
Kathleen Gordon, Do, DO
Internal Medicine — Payments: $20,027
Leah Brandon, Do, DO
Internal Medicine — Payments: $9,373
Ms. Stephanie Drainville, Pa-C, PA-C
Internal Medicine — Payments: $7,953
Dr. P Canchis, Md, MD
Internal Medicine — Payments: $6,200
Dr. Vito Ferri, D.o, D.O
Internal Medicine — Payments: $1,220
William Beliveau, M.d, M.D
Internal Medicine — Payments: $899.97